Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Sera Prognostics
SERA
Sera Prognostics
Medicaid Expansion And Maternal Health Focus Will Drive Long-Term Opportunity In Preterm Birth Prevention
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
17 Dec 25
Views
4
1
Set Fair Value
Like
votes
Share
17 Dec
US$1.80
AnalystConsensusTarget's Fair Value
US$5.00
64.0% undervalued
intrinsic discount
1Y
-56.0%
7D
2.9%
Loading
1Y
-56.0%
7D
2.9%
Author's Valuation
US$5
64.0% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$5
64.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-44m
12m
2019
2021
2023
2025
2027
2028
Revenue US$11.5m
Earnings US$1.8m
Revenue
Profit Margin
Future PE
Est. Revenue
$
Forecast revenue growth rate
54.06%
Historical revenue growth rate
-2.29%
Biotech revenue growth rate
10.88%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.24%
Calculation
US$1.84m
Earnings '28
x
138.16x
PE Ratio '28
=
US$254.83m
Market Cap '28
US$254.83m
Market Cap '28
/
41.53m
No. shares '28
=
US$6.14
Share Price '28
US$6.14
Share Price '28
Discounted to 2025 @ 7.06% p.a.
=
US$5.00
Fair Value '25